Questions About Cancer? 1-800-4-CANCER

Kaposi Sarcoma Treatment (PDQ®)

Health Professional Version
Last Modified: 04/04/2011

Changes to This Summary (04/04/2011)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Kaposi Sarcoma 1

Added Lodi et al. as reference 19 2.

Epidemic Kaposi Sarcoma 3

Added text 4 to state that during highly active antiretroviral therapy, both pegylated liposomal doxorubicin and paclitaxel are active single agents with response rates close to 50% (cited Cianfrocca et al. as reference 17 and level of evidence 1iiDiv).

Table of Links

1http://www.cancer.gov/cancertopics/pdq/treatment/kaposis/HealthProfessional/#Se
ction_1
2http://www.cancer.gov/cancertopics/pdq/treatment/kaposis/HealthProfessional/#Se
ction_11
3http://www.cancer.gov/cancertopics/pdq/treatment/kaposis/HealthProfessional/Pag
e5#Section_45
4http://www.cancer.gov/cancertopics/pdq/treatment/kaposis/HealthProfessional/Pag
e5#Section_51